Overview

TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Status:
Completed

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation